Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

  • NeuroKey-3™ measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer’s Disease and Dementia pathology, including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and more.
  • NeuroKey-3™ is a proprietary method providing absolute quantification of multiple proteins in a single IP-MS assay.
  • NeuroKey-3™ is now commercially available through Inoviv for drug developers to gather valuable data for their clinical trials.

LONDON, March 1, 2024 /PRNewswire/ — Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3™ assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma. The launch of NeuroKey-3™ signifies an important milestone in Inoviv’s mission to generate novel molecular insights that transform drug development and healthcare globally. Inoviv will unveil NeuroKey-3™ at AD/PD 2024 on March 5, 2024.

NeuroKey-3™ is the world’s first commercially available disease-targeted assay providing absolute quantification from plasma of a unique set of proteins linked to Alzheimer’s Disease and Dementia. The comprehensive assay and end-to-end service delivers highly robust and reproducible data to quantify low-level analytes and provides clinical researchers with a full biomarker report containing statistical analysis, graphical data representations, correlation matrices, and quantitative values.

Read full article on

Share this page on social

Ready to get started? See what Samba can do for you.